准分子激光斑块旋切术联合药物涂层球囊治疗股腘动脉原发病变的安全性与疗效:一项回顾性研究
该回顾性研究纳入2016年11月至2020年1月接受准分子激光斑块旋切术(ELA)联合药物涂层球囊(DCB)治疗的股腘动脉原发病变(FPAD)患者56例,平均随访37.8±25.3个月。结果显示总体技术成功率为100%,12、24、36、48个月一期通畅率分别为75%、66.1%、58.9%、42.8%,免于临床驱动的靶病变血运重建(CD-TLR)率分别为83.9%、80.3%、76.8%、57.1%。作者认为在真实世界临床实践中,ELA+DCB似乎是治疗股腘动脉原发病变安全有效的腔内治疗方式。
要点
- ELA+DCB治疗股腘动脉原发病变总体技术成功率为100%。
- 48个月一期通畅率为42.8%,免于CD-TLR率为57.1%。
- 作者认为ELA+DCB似乎是安全有效的腔内治疗选择。
核心结论
- 在真实世界临床实践中,ELA+DCB似乎是治疗股腘动脉原发病变安全有效的腔内治疗方式,免于CD-TLR率较低且通畅率良好。
研究设计与样本
- 回顾性研究,纳入2016年11月至2020年1月接受ELA+DCB治疗的股腘动脉原发病变患者56例(年龄68.23±8.01岁,男性41例),平均随访37.8±25.3个月。
主要发现
- 43例为生活方式受限的间歇性跛行,13例为慢性肢体威胁性缺血。
- 所有患者病变平均长度为178.41 mm,总病变闭塞率为48.2%(n=27)。
- 总体技术成功率为100%。
- ELA+DCB组12、24、36、48个月一期通畅率分别为75%、66.1%、58.9%、42.8%。
- 12、24、36、48个月免于CD-TLR率分别为83.9%、80.3%、76.8%、57.1%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effectiveness of excimer laser atherectomy (ELA) combined with drug-coated balloon (DCB) for de novo femoropopliteal artery disease (FPAD) is currently unknown. This case series evaluated the clinical outcomes of ELA combined with DCB in de novo FPAD from a real-world clinical perspective. METHODS: We conducted a retrospective study of patients treated with ELA + DCB for de novo FPAD between November 2016 and January 2020. The primary efficacy endpoint was the initial patency rate; secondary endpoints included target lesion revascularization without clinically driven target lesion revascularization (CD-TLR) and technical success. Primary safety endpoints included all-cause death, unplanned major amputation, and postoperative complications. RESULTS: The mean follow-up was 37.8 ± 25.3 months and included 56 consecutive patients (68.23 ± 8.01 years, 41 men). Forty-three patients had lifestyle-restricted claudication, and 13 patients had critical limb-threatening ischemia. The mean length of the lesion was 178.41 mm in all patients. The total lesion occlusion rate was 48.2 (n = 27), and the overall technical success rate was 100%. The 12-month, 24-month, 36-month, and 48-month primary patency rates of the ELA + DCB group were 75%, 66.1%, 58.9%, and 42.8%, respectively. Freedom from CD-TLR at 12, 24, 36, and 48 months was 83.9%, 80.3%, 76.8%, and 57.1%, respectively. CONCLUSIONS: In real-world clinical practice, ELA + DCB appears to be a safe and effective endovascular treatment for de novo FPAD, with a low rate of freedom from CD-TLR and a good patency rate.
引用
- Pan D, Guo J, Su Z, et al. Safety and Efficacy of Excimer Laser Atherectomy Combined with a Drug-Coated Balloon in De Novo Femoral Popliteal Artery Disease: A Retrospective Study. Ann Vasc Surg. 2023. PMID: 37914073. doi:10.1016/j.avsg.2023.09.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。